UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

UroGen Pharma's chief medical officer Mark Schoenberg sold 5,222 ordinary shares for about $143,000, disclosed in an SEC Form 4. The sale followed the exercise of 10,000 options, with a weighted average sale price of $27.30 and a post-transaction holding of 139,763 shares; no remaining exercisable options. Since May of last year, Schoenberg has completed seven insider sells, with direct holdings down about 25.8%. The stock traded near $27.30 around June 8, 2026, amid a 1-year total return of roughly 168%. UroGen develops Jelmyto and a pipeline including UGN-102 and UGN-301; Teva will license a generic Jelmyto starting Sept. 15, 2030. First-quarter Jelmyto sales rose 7%.